Men of all ages treated for prostate cancer with androgen deprivation therapy, specifically with gonadotropin-releasing hormone agonists, have an increased risk of diabetes and cardiovascular disease, according to a new study.
Men of all ages treated for prostate cancer with androgen deprivation therapy, specifically with gonadotropin-releasing hormone agonists, have an increased risk of diabetes and cardiovascular disease, according to a new study.
Leave a Reply
You must be logged in to post a comment.